Gilead
Research
Research
Our growing pipeline includes novel investigational medications for the potential treatment of HIV/AIDS, liver disease and cardiovascular and respiratory diseases.

Recent News

Visit Gilead’s newsroom for access to our most recent news.

At Gilead, we are dedicated to advancing the care of patients suffering from life-threatening diseases worldwide. Our research and development programs currently focus on therapeutics for the potential treatment of HIV/AIDS, liver disease and serious cardiovascular and respiratory conditions.

Aztreonam for Inhalation Solution
Potential indication: Cystic Fibrosis
Marketing Applications Pending
Elvitegravir
Potential indication: HIV/AIDS
Phase III
Darusentan
Potential indication: Resistant Hypertension
Phase III
Adentri®
Potential indication: Acute Heart Failure
Phase III
Ambrisentan
Potential indication: Idiopathic Pulmonary Fibrosis
Phase III
Integrase Fixed-dose Regimen (integrase inhibitor/FTC/TDF/GS 9350)
Potential indication: HIV/AIDS
Phase II
GS 9350 (pharmacoenhancer)
Potential indication: HIV/AIDS
Phase II
GS 9450 (caspase inhibitor)
Potential indication: Hepatitis C/Fibrosis
Phase II
GS 9450 (caspase inhibitor)
Potential indication: Nonalcoholic steatohepatitis
Phase II
GS 9190 (polymerase inhibitor)
Potential indication: Hepatitis C
Phase II
Cicletanine
Potential indication: Pulmonary Arterial Hypertension
Phase II
Tecadenoson
Potential indication: Atrial Fibrillation
Phase II
Aztreonam for Inhalation Solution
Potential indication: Bronchietasis
Phase II
GS 9310/11 (inhaled fosfomycin/tobramycin)
Potential indication: Cystic Fibrosis
Phase II
GS 9411 (epithelial sodium channel blocker)
Potential indication: Pulmonary disease
Phase I
CVT 6883
Potential indication: Pulmonary disease
Phase I
CVT 3619
Potential indication: Diabetes
Phase I